Metallothionein, an endogenous antioxidant, protects against retinal neuron damage in mice

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 9, 2006, Pages 3975-3982

  Suemori, Shinsuke ^a,b   Shimazawa, Masamitsu ^a   Kawase, Kazuhide ^b   Satoh, Masahiko ^a   Nagase, Hisamitsu ^b   Yamamoto, Tetsuya ^a   Hara, Hideaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; CALCITRIOL; CYSTEINE; GLUTAMIC ACID; GLUTATHIONE; MESSENGER RNA; METALLOTHIONEIN I; METALLOTHIONEIN II; N METHYL DEXTRO ASPARTIC ACID; ZINC SULFATE; ANTIOXIDANT; COLECALCIFEROL; METALLOTHIONEIN; N METHYLASPARTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DEATH; CELL LOSS; CELL STRAIN; CELL STRAIN RGC 5; COMPARATIVE STUDY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INHIBITION KINETICS; MALE; MOLECULAR RECOGNITION; MOUSE; MOUSE STRAIN; NERVE CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINA; RETINA GANGLION CELL; RETINA INJURY; RETINA INNER PLEXIFORM LAYER; RETINA NERVE CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE; ANIMAL; C57BL MOUSE; CELL SURVIVAL; CHEMICALLY INDUCED DISORDER; CULTURE TECHNIQUE; DRUG EFFECT; ENZYME IMMUNOASSAY; GENETICS; INJECTION; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; RETINA DISEASE; UPREGULATION; VITREOUS BODY;

ANIMALS; ANTIOXIDANTS; BUTHIONINE SULFOXIMINE; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CHOLECALCIFEROL; GLUTAMIC ACID; IMMUNOENZYME TECHNIQUES; INJECTIONS; MALE; METALLOTHIONEIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; N-METHYLASPARTATE; OXIDATIVE STRESS; RETINAL DISEASES; RETINAL GANGLION CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; VITREOUS BODY; ZINC SULFATE;

EID: 33749132814     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0275     Document Type: Article

References (37)

1. Dreyer EB, Zurakowski D, Schumer RA, et al. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299-305.
2. Dreyer EB. A proposed role for excitotoxicity in glaucoma. J Glaucoma. 1998;7:62-67.
3. Bonfoco E, Krainc D, Ankarcrona M, et al. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA. 1995;92:7162-7166.
4. Bastianetto S, Quirion R. Natural antioxidants and neurodegenerative diseases. Front Biosci. 2004;9:3447-3452.
5. Selim MH, Ratan RR. The role of iron neurotoxicity in ischemic stroke. Ageing Res Rev. 2004;3:345-353.
6. HaMai D, Bondy SC. Oxidative basis of manganese neurotoxicity. Ann N Y Acad Sci. 2004;1012:129-141.
7. Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother. 2003;57:145-155.
8. Pompella A, Visvikis A, Paolicchi A, et al. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol. 2003;66:1499-1503.
9. Harding JJ. Free and protein-bound glutathione in normal and cataractous human lenses. Biochem J. 1970;117:957-960.
10. Donma O, Yorulmaz E, Pekel H, Suyugul N. Blood and lens lipid peroxidation and antioxidant status in normal individuals, senile and diabetic cataractous patients. Curr Eye Res. 2002;25:9-16.
11. Gherghel D, Griffiths HR, Hilton EJ, et al. Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2005;46:877-883.
12. Cicik E, Tekin H, Akar S, et al. Interleukin-8, nitric oxide and glutathione status in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Ophthalmic Res. 2003;35:251-255.
13. Nowak M, Swietochowska E, Wielkoszynski T, et al. Changes in blood antioxidants and several lipid peroxidation products in women with age-related macular degeneration. Eur J Ophthalmol. 2003;13:281-286.
14. Kagi JH, Vallee BL. Metallothionein: a cadmium and zinc-containig protein from equine renal cortex. II Physico-chemical properties. J Biol Chem. 1961;236:2435-2442.
15. Klaassen CD, Lehman-McKeeman LD. Regulation of the isoforms of metallothionein. Biol Trace Elem Res. 1989;21:119-129.
16. Hidalgo J, Dingman A, Garvey JS. Preparative isolation of adult human liver metallothionein isoforms. Rev Esp Fisiol. 1989;45:255-263.
17. Palmiter RD, Findley SD, Whitmore TE, Durnam DM. MT-III, a brain-specific member of the metallothionein gene family. Proc Natl Acad Sci USA. 1992;89:6333-6337.
18. Vasak M. Advances in metallothionein structure and functions. J Trace Elem Med Biol. 2005;19:13-17.
19. Thornalley PJ, Vasak M. Possible role for metallothionein in protection against radiation-induced oxidative stress: kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. Biochim Biophys Acta. 1985;827:36-44.
20. Bremner I. Nutritional and physiologic significance of metallothionein. Methods Enzymol. 1991;205:25-35.
21. Hamer DH. Metallothionein. Annu Rev Biochem. 1986;55:913-951.
22. Dunn MA, Blalock TL, Cousins RJ. Metallothionein. Proc Soc Exp Biol Med. 1987;185:107-119.
23. Campagne MV, Thibodeaux H, van Bruggen N, et al. Increased binding activity at an antioxidant-responsive element in the metallothionein-1 promoter and rapid induction of metallothionein-1 and -2 in response to cerebral ischemia and reperfusion. J Neurosci. 2000;20:5200-5207.
24. van Lockeren Campagne M, Thibodeaux H, van Bruggen N, et al. Evidence for a protective role of metallothionein-1 in focal cerebral ischemia. Proc Natl Acad Sci USA. 1999;96:12870-12875.
25. Masters BA, Kelly EJ, Quaife CJ, et al. Targeted disruption of metallothionein I and II genes increases sensitivity to cadmium. Proc Natl Acad Sci USA. 1994;91:584-588.
26. Shimazawa M, Yamashima T, Agarwal N, Hara H. Neuroprotective effects of minocycline against in vitro and in vivo retinal ganglion cell damage. Brain Res. 2005;1053:185-194.
27. Kramer KK, Zoelle JT, Klaassen CD. Induction of metallothionein mRNA and protein in primary murine neuron cultures. Toxicol Appl Pharmacol. 1996;141:1-7.
28. Karasawa M, Hosoi J, Hashiba H, et al. Regulation of metallothionein gene expression by 1 alpha,25-dihydroxyvitamin D3 in cultured cells and in mice. Proc Natl Acad Sci USA. 1987;84:8810-8813.
29. Maher P, Hanneken A. The molecular basis of oxidative stress-induced cell death in an immortalized retinal ganglion cell line. Invest Ophthalmol Vis Sci. 2005;46:749-757.
30. Choi DW. Excitotoxic cell death. J Neurobiol. 1992;23:1261-1276.
31. Wallin C, Weber SG, Sandberg M. Glutathione efflux induced by NMDA and kainate: implications in neurotoxicity? J Neurochem. 1999;73:1566-1572.
32. Trendelenburg G, Prass K, Priller J, et al. Serial analysis of gene expression identifies metallothionein-II as major neuroprotective gene in mouse focal cerebral ischemia. J Neurosci. 2002;22:5879-5888.
33. Michalska AE, Choo KH. Targeting and germ-line transmission of a null mutation at the metallothionein I and II loci in mouse. Proc Natl Acad Sci USA. 1993;90:8088-8092.
34. Sato M, Bremner I. Oxygen free radicals and metallothionein. Free Radic Biol Med. 1993;14:325-337.
35. Andrews GK. Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem Pharmacol. 2000;59:95-104.
36. Ogawa T, Mimura Y. Antioxidant effect of zinc on acute renal failure induced by ischemia-reperfusion injury in rats. Am J Nephrol. 1999;19:609-614.
37. Hanada K, Sawamura D, Nakano H, Hashimoto I. Possible role of 1,25-dihydroxyvitamin D3-induced metallothionein in photoprotection against UVB injury in mouse skin and cultured rat keratinocytes. J. Dermatol Sci. 1995;9:203-208.